Sign In
Buy DMAC
$6.34
-0.170 (-2.61%)
At Close: Jul 31, 2026
New Strong Buy Stocks for October 14th
09:43am, Monday, 14'th Oct 2024
HQI, CLPR, HIVE, DMAC and IAG have been added to the Zacks Rank #1 (Strong Buy) List on October 14, 2024.
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
08:27am, Wednesday, 09'th Oct 2024
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announce
DiaMedica Therapeutics Upcoming Conference Participation
04:15pm, Wednesday, 04'th Sep 2024
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?
10:42am, Thursday, 01'st Aug 2024
Here is how DiaMedica Therapeutics, Inc. (DMAC) and Elutia Inc. (ELUT) have performed compared to their sector so far this year.
DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point
02:48pm, Thursday, 11'th Jul 2024
An interim futility analysis by the DSMB of DM199 for patients with AIS in the phase 2/3 ReMEDy2 trial is expected by Q1 of 2025. The global acute ischemic stroke therapeutics market size is expected
DiaMedica Therapeutics Announces $11.8 Million Private Placement
08:15am, Wednesday, 26'th Jun 2024
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announce
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
08:00am, Wednesday, 26'th Jun 2024
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announce
DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript
04:49pm, Saturday, 11'th May 2024
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Rick Pauls - President, CEO & Director Lorianne Masuoka - Chief Medical Officer S
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
08:55am, Thursday, 02'nd May 2024
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
11:10am, Thursday, 18'th Apr 2024
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Monday, 15'th Apr 2024
DiaMedica Therapeutics (DMAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni
Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
06:00am, Saturday, 23'rd Mar 2024
The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of th
DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript
04:14pm, Wednesday, 20'th Mar 2024
DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
09:53pm, Tuesday, 19'th Mar 2024
DiaMedica Therapeutics (NASDAQ: DMAC ) just reported results for the fourth quarter of 2023. DiaMedica Therapeutics reported earnings per share of -14 cents.
